Nephros Sees 40% Increase In Q2 Sales, Submits HDF Product For FDA Approval

Nephros Inc NEPH has announced preliminary results and expects Q2 sales of approximately $2.2 million, representing a Y/Y increase of 40%
"Revenue growth seems to be returning to pre-pandemic levels. In addition, revenue for the six months ended June 30, 2021, is expected to be over $5 million, a 20% increase over the same periods in 2020 and 2019, which we believe puts us in a strong position going into the second half of the year", said CEO Andy Astor.
In addition, the Company submitted its Hemodiafiltration (HDF) System Assist Module for FDA 510(k) clearance.
"Pending this FDA clearance, SRP is preparing for commercial launch at a limited number of dialysis clinics."
Nephros ended the second quarter with approximately $8.3 million in cash on a consolidated basis.
Nephros will formally announce its second-quarter results on August 5.
Price Action: NEPH shares are down 0.95% at $9.55 on the last check Thursday.

Momentum60.37

Growth39.85

Quality-

Value10.34

Short

Medium

Long

Earnings Calendar